A DNA damage repair gene‐associated signature predicts responses of patients with advanced soft‐tissue sarcoma to treatment with trabectedin
暂无分享,去创建一个
J. Dopazo | J. Martín-Broto | C. Romagosa | C. Valverde | A. de Juan | M. Peña-Chilet | Juan A. Cordero Varela | S. Bagué | R. Álvarez-Alegret | D. Moura | N. Hindi | L. Vicioso | J. Lavernia | A. Gutiérrez | R. Álvarez | J. Martínez-Trufero | S. Lacerenza | F. Izquierdo | R. Ramos | J. Rubió-Casadevall | L. Ortega-Medina | M. V. Vaz Salgado | F. Martín-Dávila | C. Agra-Pujol | J. Barceló | C. Hernández-León | M. López-Álvarez | Carolina Castilla-Ramirez | Empar Mayodormo-Aranda | Maria Concepcion Fiaño-Valverde
[1] J. Martín-Broto,et al. CUL4A, ERCC5, and ERCC1 as Predictive Factors for Trabectedin Efficacy in Advanced Soft Tissue Sarcomas (STS): A Spanish Group for Sarcoma Research (GEIS) Study , 2020, Cancers.
[2] Robin L. Jones,et al. Different approaches to advanced soft tissue sarcomas depending on treatment line, goal of therapy and histological subtype , 2020, Expert review of anticancer therapy.
[3] J. Blay,et al. Assessment of Safety and Efficacy of Combined Trabectedin and Low-Dose Radiotherapy for Patients With Metastatic Soft-Tissue Sarcomas: A Nonrandomized Phase 1/2 Clinical Trial. , 2020, JAMA oncology.
[4] Dongyun He,et al. Exonuclease 1 (Exo1) Participates in Mammalian Non-Homologous End Joining and Contributes to Drug Resistance in Ovarian Cancer , 2020, Medical science monitor : international medical journal of experimental and clinical research.
[5] J. Blay,et al. Trabectedin and RAdiotherapy in Soft Tissue Sarcoma (TRASTS): Results of a Phase I Study in Myxoid Liposarcoma from Spanish (GEIS), Italian (ISG), French (FSG) Sarcoma Groups , 2019, EClinicalMedicine.
[6] S. Elledge,et al. Genetic Screens Reveal FEN1 and APEX2 as BRCA2 Synthetic Lethal Targets. , 2019, Molecular cell.
[7] C. Galmarini,et al. The Antitumor Drugs Trabectedin and Lurbinectedin Induce Transcription-Dependent Replication Stress and Genome Instability , 2018, Molecular Cancer Research.
[8] Y. D'Alessandra,et al. Direct screening of plasma circulating microRNAs , 2018, RNA biology.
[9] M. Zucchetti,et al. Trabectedin and olaparib in patients with advanced and non-resectable bone and soft-tissue sarcomas (TOMAS): an open-label, phase 1b study from the Italian Sarcoma Group. , 2018, The Lancet. Oncology.
[10] B. Kerns,et al. Developmental profiling of microRNAs in the human embryonic inner ear , 2018, PloS one.
[11] Md Akram Hossain,et al. APE2 promotes DNA damage response pathway from a single-strand break , 2018, Nucleic acids research.
[12] J. Cogswell,et al. Evaluation and selection of a non-PCR based technology for improved gene expression profiling from clinical formalin-fixed, paraffin-embedded samples. , 2016, Bioanalysis.
[13] S. Pignata,et al. Prospective phase II trial of trabectedin in BRCA-mutated and/or BRCAness phenotype recurrent ovarian cancer patients: the MITO 15 trial. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.
[14] C. Galmarini,et al. Unique features of trabectedin mechanism of action , 2016, Cancer Chemotherapy and Pharmacology.
[15] F. Bertucci,et al. BRCA1 haplotype and clinical benefit of trabectedin in soft-tissue sarcoma patients , 2015, British Journal of Cancer.
[16] Kai Huang,et al. Identification of Poly(ADP-Ribose) Polymerase-1 as a Cell Cycle Regulator through Modulating Sp1 Mediated Transcription in Human Hepatoma Cells , 2013, PloS one.
[17] N. Penel,et al. Efficacy and safety of pharmacological interventions in second- or later-line treatment of patients with advanced soft tissue sarcoma: a systematic review , 2013, BMC Cancer.
[18] Antonio Nieto,et al. Trabectedin in patients with advanced non-small-cell lung cancer (NSCLC) with XPG and/or ERCC1 overexpression and BRCA1 underexpression and pretreated with platinum. , 2012, Lung cancer.
[19] J. Blay,et al. ERCC5/XPG, ERCC1, and BRCA1 gene status and clinical benefit of trabectedin in patients with soft tissue sarcoma , 2011, Cancer.
[20] J. Besalduch,et al. Yondelis® (ET-743, Trabectedin) sensitizes cancer cell lines to CD95-mediated cell death: new molecular insight into the mechanism of action. , 2011, European journal of pharmacology.
[21] J. Blay,et al. Predictive impact of DNA repair functionality on clinical outcome of advanced sarcoma patients treated with trabectedin: a retrospective multicentric study. , 2011, European journal of cancer.
[22] C. E. Schrader,et al. Apurinic/Apyrimidinic Endonuclease 2 Is Necessary for Normal B Cell Development and Recovery of Lymphoid Progenitors after Chemotherapeutic Challenge , 2011, The Journal of Immunology.
[23] V. Schreiber,et al. Poly(ADP-ribose) polymerase 3 (PARP3), a newcomer in cellular response to DNA damage and mitotic progression , 2011, Proceedings of the National Academy of Sciences.
[24] Robin L. Jones,et al. Clinical Benefit of Second-Line Palliative Chemotherapy in Advanced Soft-Tissue Sarcoma , 2010, Sarcoma.
[25] P. Allavena,et al. Antitumor and anti-inflammatory effects of trabectedin on human myxoid liposarcoma cells. , 2010, Cancer research.
[26] M. Robinson,et al. A scaling normalization method for differential expression analysis of RNA-seq data , 2010, Genome Biology.
[27] J. Blay,et al. Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[28] M. Rossi,et al. Poly(ADP-ribosyl)ation is implicated in the G0–G1 transition of resting cells , 2008, Oncogene.
[29] J. Blay,et al. Phase I Combination Study of Trabectedin and Doxorubicin in Patients with Soft-Tissue Sarcoma , 2008, Clinical Cancer Research.
[30] R. Sánchez-Prieto,et al. In vitro radiosensitisation by trabectedin in human cancer cell lines. , 2008, European journal of cancer.
[31] M. Robinson,et al. Small-sample estimation of negative binomial dispersion, with applications to SAGE data. , 2007, Biostatistics.
[32] G. Poirier,et al. PARP‐3 associates with polycomb group bodies and with components of the DNA damage repair machinery , 2007, Journal of cellular biochemistry.
[33] P. Allavena,et al. Anti-inflammatory properties of the novel antitumor agent yondelis (trabectedin): inhibition of macrophage differentiation and cytokine production. , 2005, Cancer research.
[34] C. Simbulan-Rosenthal,et al. PARP-1 binds E2F-1 independently of its DNA binding and catalytic domains, and acts as a novel coactivator of E2F-1-mediated transcription during re-entry of quiescent cells into S phase , 2003, Oncogene.
[35] J. Vonesch,et al. PARP-3 localizes preferentially to the daughter centriole and interferes with the G1/S cell cycle progression , 2003, Journal of Cell Science.
[36] J. Pačes,et al. Cloning and expression of PARP-3 (Adprt3) and U3-55k, two genes closely linked on mouse chromosome 9. , 2002, Folia biologica.
[37] Y. Pommier,et al. Antiproliferative activity of ecteinascidin 743 is dependent upon transcription-coupled nucleotide-excision repair , 2001, Nature Medicine.
[38] M D'Incalci,et al. Ecteinascidin-743 (ET-743), a natural marine compound, with a unique mechanism of action. , 2001, European journal of cancer.
[39] R. Mantovani,et al. Interference of transcriptional activation by the antineoplastic drug ecteinascidin-743. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[40] M. Johansson. A human poly(ADP-ribose) polymerase gene family (ADPRTL): cDNA cloning of two novel poly(ADP-ribose) polymerase homologues. , 1999, Genomics.
[41] E. Nigg,et al. MAT1, cdk7 and cyclin H form a kinase complex which is UV light‐sensitive upon association with TFIIH. , 1996, The EMBO journal.
[42] Y. Benjamini,et al. Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .